论文部分内容阅读
因湘、粤、川等地连续出现疑似乙肝疫苗致死病例,2013年12月19日下午,国家食品药品监督管理总局(以下简称“国家食药监局”)一则通知,暂停使用深圳康泰生物制品公司(以下简称“深圳康泰”)生产的全部批次重组乙型肝炎疫苗产品。“暂停使用深圳康泰全部批次乙肝疫苗是一个负责任的行动,说明国家已经认识到问题比较严重,应高度警惕。”中国疾病预防控制中心流行病学首席专家曾光
In the afternoon of December 19, 2013, on the afternoon of December 19, 2013, the State Food and Drug Administration (hereinafter referred to as the “State Food and Drug Administration”) informed of the suspension of the use of Shenzhen Kangtai Biological Products Company (hereinafter referred to as “Shenzhen Kangtai”) produced all batches of recombinant hepatitis B vaccine products. “Suspension of all batches of Shenzhen Kangtai Hepatitis B vaccine is a responsible action, indicating that the country has recognized the problem is more serious, should be highly vigilant. ” China Center for Disease Control and Prevention Chief Expert Zeng Guang